Nasdaq Extends Deadline for CombiMatrix to Meet Listing Requirement | GenomeWeb

NEW YORK (GenomeWeb News) – Nasdaq has granted CombiMatrix an extension to provide evidence that it is in compliance with a listing requirement, the company said in a regulatory document on Thursday.

In a filing with the US Securities and Exchange Commission, CombiMatrix said that Nasdaq has given it until Aug. 20 to provide evidence in its Form 10-Q for the second quarter ending June 30 that it complies with a rule calling for at least $2.5 million in stockholders' equity in order to remain listed on the exchange.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: transcriptional and translational study of human cytomegalovirus interactions with host cells, spider web DNA study, and more.

The New York Stem Cell Foundation signs a lease for a new space.

Researchers gear up for an international meeting to discuss the ethics of gene editing.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

Sponsored by
Agilent Technologies

This online seminar will discuss a metagenomic assay to identify viruses and other pathogenic microorganisms in human tumor samples, with the aim of gaining a more comprehensive understanding of the role of the microbiome in cancer development and treatment.